| P2093 | author name string | Hui Shen | |
| | Zui Zou | |
| | Ping Liu | |
| | Mao Mao An | |
| | Yuan Ying Jiang | |
| | Yong Bing Cao | |
| | Meng Li Chen | |
| P2860 | cites work | Tumor angiogenesis: therapeutic implications | Q27860595 |
| | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | Meta-analysis in clinical trials | Q27860779 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 |
| | Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 |
| | Role of angiogenesis in tumor growth and metastasis | Q29614309 |
| | Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 |
| | Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 |
| | Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial | Q34555503 |
| | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 |
| | Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 |
| | Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil | Q34935734 |
| | Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer | Q36024588 |
| | A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 |
| | Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis | Q36721468 |
| | Why sources of heterogeneity in meta-analysis should be investigated | Q36888653 |
| | Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis | Q37067792 |
| | Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 | Q37117085 |
| | Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis | Q37254387 |
| | Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. | Q40459711 |
| | Assessing the quality of randomized controlled trials. Current issues and future directions | Q40960250 |
| | The importance of quality of primary studies in producing unbiased systematic reviews | Q40986391 |
| | Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer | Q45106840 |
| | von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma | Q46478024 |
| | Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer | Q46502913 |
| | Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer | Q46972019 |
| | Summing up evidence: one answer is not always enough. | Q52900179 |
| | Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 |
| P433 | issue | 8 | |
| P921 | main subject | bevacizumab | Q413299 |
| | meta-analysis | Q815382 |
| P304 | page(s) | 813-821 | |
| P577 | publication date | 2010-04-17 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis | |
| P478 | volume | 66 | |